| Date | Title | Description |
| 17.08.2026 | How Heidi built production-ready AI for healthcare at global scale | Presented by MongoDB
Building AI that is accurate, secure, and reliable is a major engineering feat for organizations subject to the compliance obligations that govern healthcare, financial services, and transportation. The challenge of del... |
| 11.08.2026 | Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe | Eli Lilly’s Foundayo won U.K. approval, becoming Europe’s second GLP-1 weight-loss pill and its first approval in the continent
Foundayo will initially be available privately by prescription, with NHS access dependent on a cost-effectivenes... |
| 04.08.2026 | Family History Cannot Find 95% of Breast Cancer in Women Under 50, Landmark Study Finds | By Joseph Blake
Published: Aug 04 2026, 4:05 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 15.07.2026 | Tau Therapy Slows Alzheimer’s Decline in First Human Trial as AAIC 2026 Wraps in London | By Ronald Holman
Published: Jul 15 2026, 11:50 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 14.07.2026 | Англия, возможно, больше не будет закупать дорогой препарат от рака легких | Англия, возможно, больше не будет закупать дорогой препарат от рака легких Регулятор счел траты экономически необоснованными
Британский Национальный институт здоровья и совершенствования медицинской помощи (NICE) опубликовал проект рекоменд... |
| 08.04.2026 | CNBC’s UK Exchange newsletter: Brace yourself for rising bills as new tax year kicks off | The new tax year has kicked off in the U.K.
Households and businesses are facing rising bills due to a range of measures introduced by the Labour government.
There will be some winners with mobile and broadband suppliers and water companies... |
| 03.04.2026 | GLP-1 Revolution: Novo Nordisk Innovates Pricing, Expands Health Impact | Novo Nordisk aggressively reshapes the GLP-1 landscape. It launches multi-month Wegovy subscriptions in the U.S., ensuring predictable pricing and bolstering patient adherence against Eli Lilly's market dominance. Concurrently, the UK's NIC... |
| 01.04.2026 | Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people | Novo Nordisk weight loss drug Wegovy was recommended by England’s drug price regulator to prevent heart attacks and strokes.
The new recommendation from NICE will significantly expand access to Wegovy on the country’s National Health Servic... |
| 23.02.2026 | NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy | NICE Recommends TEPKINLY[®] ▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
Mon, Feb 23, 2026 10:51 CET Report this content
E... |
| 21.02.2026 | Digital Mental Health Pioneer Secures $23.7M to Transform Care Access | Big Health raised $23.7 million. This funding will scale its FDA-cleared digital mental health treatments. SleepioRx targets insomnia. DaylightRx addresses generalized anxiety. A recent Centers for Medicare & Medicaid Services policy ch... |
| 15.02.2026 | Big Health Secures $23.7 Million To Scale FDA-Cleared Treatments | Big Health announced it has secured $23.7 million in new strategic funding to accelerate the adoption of its FDA-cleared digital mental health treatments, as health systems increasingly integrate reimbursable digital care into routine pract... |
| 27.01.2026 | Can You Trust Digital Tools With Your Mental Health? | New advice on using apps and other digital tools to support mental health is being published by the Medicines and Healthcare products Regulatory Agency (MHRA), as part of free online resources developed with NHS England for the public, pare... |
| 24.01.2026 | Как кубик Рубика влияет на мозг: развитие нейропластичности и когнитивных способностей | Кубику Рубика уже более полувека, но эта головоломка продолжает захватывать умы и молодых, и взрослых. Когда в 1974 году Эрнё Рубик изобретал «Волшебный куб» для развития пространственного мышления у своих студентов, он вряд ли предполагал,... |
| 03.12.2025 | Britain is missing out on pharma investment thanks to medicine rationing | A subtle version of fiscal drag has seen the amount the NHS is prepared to spend on treatments reduce in real terms, meaning patients are missing out on life-saving treatment and the economy is missing out on investment, says Gareth Lyon
Th... |
| 03.12.2025 | Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible adult patients with a previously treated subtype of locally advanced or metastatic cholangiocar... | For United Kingdom (UK) Trade and Medical Media Only
Taiho Oncology Europe GmbH announced today the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor.1,3 This development follows... |
| 08.10.2025 | Ministers planning drug pricing shake-up to stem pharma exodus | Ministers are drawing up a radical overhaul of NHS spending rules in a bid to shore up the UK’s world-leading life sciences industry after a string of pharma giants cancelled major UK investment projects.
In what would amount to one of the ... |
| 13.09.2025 | As insurers struggle with GLP-1 drug costs, some seek to wean patients off | By Jamie Ducharme, KFF Health News
After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April.
Her request for coverage had been denied, the... |
| 10.09.2025 | Innovate UK backs Hormona with £100K grant for menopause diagnostics | Hormona, a UK-based healthtech developing personalised hormone tracking solutions, has received a £100,000 grant from Innovate UK to support development of its hormone tracking technology.
The funding will support development of the company... |
| 14.08.2025 | Implantica publishes Interim Report January – June 2025 (Q2) | Implantica publishes Interim Report January – June 2025 (Q2)
Thu, Aug 14, 2025 08:00 CET Report this content
Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum
Significant events in the second quarter of 2025
FDA... |
| 04.06.2025 | Implantica announces that UK NICE has published positive recommendations for the RefluxStop™ procedure in the NHS public hospitals | Implantica announces that UK NICE has published positive recommendations for the RefluxStop™ procedure in the NHS public hospitals
Wed, Jun 04, 2025 08:00 CET Report this content
Implantica AG (publ.), providing the unique device RefluxStop... |
| 25.04.2025 | Businesses, get back to work! WFH is harming young people | If you care about young people, get your workers back to the office. WFH is hindering their development, writes Joanna Jensen
The government is faced with 2.8m economically inactive individuals due to long-term sickness, including a strikin... |
| 22.04.2025 | As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers? | For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks.
The pharmaceutical industry has been left in a particularly agonising... |
| 21.04.2025 | 11 New Robotic Surgery Systems Get NHS Green Light | Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
The technology, which is capable of movements more precis... |
| 18.01.2025 | Medicare's Drug Price Negotiations: A New Era for Prescription Costs | In a significant shift, Medicare is stepping into the ring to negotiate drug prices. This change aims to alleviate the financial burden on millions of seniors. The latest announcement includes 15 new drugs, bringing the total to 25. These d... |
| 13.01.2025 | AbbVie’s SKYRIZI[®] (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie’s SKYRIZI[®] (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Mon, Jan 13, 2025 12:16 CET Report this content
PRESS RELEASE – For UK consumer health, medica... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 22.08.2024 | AbbVie’s SKYRIZI[®] (risankizumab) Is Recommended by NICE as an Option for Use in Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie’s SKYRIZI[®] (risankizumab) Is Recommended by NICE as an Option for Use in Adults with Moderately to Severely Active Ulcerative Colitis
Thu, Aug 22, 2024 16:04 CET Report this content
For UK consumer, medical and trade media only
In ... |
| 21.08.2024 | Implantica publishes Interim Report January – June 2024 (Q2) | Implantica publishes Interim Report January – June 2024 (Q2)
Wed, Aug 21, 2024 08:00 CET Report this content
RefluxStop™ is on a wave of success – carried by a multitude of published studies with excellent outcomes from leading European Ref... |
| 20.08.2024 | Seguimiento de los Datos del NEJM Sobre la Mini-cinta de una Sola Incisión | Dr. Greg Vigna
Los datos subyacentes compararon las complicaciones de las cintas retropúbicas con las cintas transobturadoras y compararon la mini-cinta Altis con la Bard
El grupo de mini-sling en el estudio ampliamente citado del Dr. Abdel... |
| 07.08.2024 | Global Evolution of Real-World Data/Evidence in Regulatory Approval and Health Technology Assessments, Upcoming Webinar Hosted by Xtalks | www.anlitiks.com
In this free webinar we will explore the evolving global guidelines and frameworks on the use of real-world data/evidence (RWD/E) in regulatory decision-making and health technology assessments (HTA).
TORONTO, Aug. 7, 2024 ... |
| 12.07.2024 | New UK Labour government will focus on healthtech and dementia treatment as part of UK healthcare reform | New UK Labour government will focus on healthtech and dementia treatment as part of UK healthcare reform
Fri, Jul 12, 2024 10:31 CET Report this content
Copenhagen, Denmark, 12 July 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
Building a ... |
| 09.07.2024 | The CST Assistant v2.0 for Cognitive Stimulation Therapy (CST) now released in Denmark | The CST Assistant v2.0 for Cognitive Stimulation Therapy (CST) now released in Denmark
Tue, Jul 09, 2024 10:18 CET Report this content
Copenhagen, Denmark, 9 July 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
The new version of the CST Ass... |
| 25.06.2024 | Как страх бустит продажи CGM (Continious Glucose Monitoring) | CGM — это устройство непрерывного мониторинга уровня глюкозы, который стал безумно популярным среди адептов здорового образа жизни, спортсменов и всех, кто боится сахара в еде.
Это маленький сенсор, который прикрепляется к телу (чаще на пле... |
| 12.06.2024 | YAZEN HEALTH RESEARCH REVEALS OVER A THIRD OF BRITS WRONGLY BELIEVE OBESITY IS A PERSONAL CHOICE | YAZEN HEALTH RESEARCH REVEALS OVER A THIRD OF BRITS WRONGLY BELIEVE OBESITY IS A PERSONAL CHOICE
Wed, Jun 12, 2024 09:04 CET Report this content
New survey uncovers widespread misunderstandings around obesity as a disease
LONDON, 12th June ... |
| 10.06.2024 | SMC Approves First Subcutaneous Bispecific Treatment Option Tepkinly[® ]▼(epcoritamab) for Adults with an Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy | SMC Approves First Subcutaneous Bispecific Treatment Option Tepkinly[® ]▼(epcoritamab) for Adults with an Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy
Mon, Jun 10, 2024 11:09 CET Report this content For the fi... |
| 28.05.2024 | A product sold every seven seconds: How Skin Control is helping users put their best face forward | Left: Michael Porter of Skin Control. Source: Supplied. article-article-body
Skin Control co-founder Michael Porter estimates his skincare brand has helped to clear up more than 132 million pimples in the last two years.
Sydney-based Skin C... |
| 16.05.2024 | Brain+ informs of progress on its UK focused proof-of-business strategy plan | Brain+ informs of progress on its UK focused proof-of-business strategy plan
Thu, May 16, 2024 11:02 CET Report this content
Copenhagen, Denmark, 16 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
Supportive early user feedback from the ... |
| 15.04.2024 | First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial | Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease
Enrolment in XanaCIDD phase 2a trial of cogn... |
| 11.04.2024 | AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults | AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults
Thu, Apr 11, 2024 08:00 CET Report this content
PRESS RELEASE - For UK consumer, medical and trade media only
The National Institute for Health ... |
| 02.04.2024 | UK Diabetes Patients Will Soon be Offered an Artificial Pancreas | Aldohn Domingo, Tech Times 02 April 2024, 12:04 am
United Kingdom's Diabetes 1 patients may soon better manage their conditions with an artificial pancreas, as the new technology is reportedly set to be offered by the country's National Hea... |
| 18.03.2024 | Brain+ strategy update: Focus on the UK to reach proof-of-business and commercial scaling in 2024-2025 | Brain+ strategy update: Focus on the UK to reach proof-of-business and commercial scaling in 2024-2025
Mon, Mar 18, 2024 10:06 CET Report this content
The UK is assessed to be the most attractive and accessible market for Brain+’ digital de... |
| 11.03.2024 | AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease | AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease
Mon, Mar 11, 2024 12:12 CET Report this content
For Medical and Trade media.
... |
| 01.02.2024 | NICE Recommends Subcutaneous Treatment Option Tepkinly[®]▼(epcoritamab) for Eligible* Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy | NICE Recommends Subcutaneous Treatment Option Tepkinly[®]▼(epcoritamab) for Eligible* Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy
Thu, Feb 01, 2024 09:48 CET Report this content
For the first time... |
| 23.01.2024 | What the health care sector is selling to Wall Street: The "first trillion-dollar drug company is out there" | Every year, thousands of bankers, venture capitalists, private equity investors and other moneybags flock to San Francisco's Union Square to pursue deals.
Scores of security guards keep the homeless, the snoops and the patent-stealers at ba... |
| 05.01.2024 | Follow-up on the Single-incision Mini-Sling NEJM Data | The underlying data compared complications of the retropubic slings with transobturator slings and compared the Altis mini-sling to Bard’s mini-sling.
The mini-sling group in Dr. Abdel-Fattah’s widely cited study causes dyspareunia 2.5x mor... |
| 06.11.2023 | Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines | Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value of life-saving cystic fibrosis medicines.
In draft guidance published late last week, the National Institute for Health and Care Excellence stated th... |
| 11.08.2023 | A.I. Cancer Technology Gets The Green Light In England | Radiologist looking at a CT scan of a patient's torso.getty |
| 09.08.2023 | No Clear Benefit, But Serious Side Effects Common for Older People Taking Antidepressants, Study Finds | Recent evidence indicates that antidepressants have little, if any, benefit over placebos for older adults, while adverse effects are more common and more serious for this age group.
Older adults risk more serious side effects from taking a... |
| 31.07.2023 | Béa Fertility raises £2.5 million to launch its at-home fertility treatment in the UK | Béa Fertility is providing an alternative to In vitro fertilisation (IVF) and Intrauterine Insemination (IUI) procedures with its at-home fertility kit for those trying to start a family. This allows the user to perform Intracervical Insemi... |
| 31.07.2023 | Béa Fertility wants to provide an at-home alternative to IVF. Check out the 9-slide pitch deck the startup used to secure $3.2 million. | Tess Cosad, cofounder and CEO of Béa Fertility. William Walsh. This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
London-based Béa Fertility has raised $3.2 million in fresh funding from Oct... |
| 25.05.2023 | Primary Care Doctors Advised Not to Prescribe Antidepressants to Patients on First Visit for Mild to Moderate Depression | Researchers suggest that instead of antidepressants, which have limited benefit to patients and carry the risks of serious side effects, doctors could prescribe physical activity first for treating mild to moderate depression.
A landmark 20... |
| 11.05.2023 | Smartphone psychotherapy trial with MGH reveals multiple patterns of effective engagement in mental health treatment | Building on previous research on the effectiveness of smartphone-delivered CBT to reduce the severity of Body Dysmorphic Disorder, a new study by Massachusetts General Hospital and Koa Health found multiple ways of engaging with therapy app... |
| 10.05.2023 | Why buzzy weight-loss drugs such as Ozempic and Wegovy cost so much more in the US | Semaglutide is a weekly injection that mimics a hunger-regulating hormone in the body. Insider
Redeem now
Trendy weight-loss drugs cost much more in the US than in other countries.
The price of semaglutide, the drug sold as Wegovy, was thre... |
| 08.05.2023 | Boston Scientific and Physician Hit with Midurethral Sling Lawsuit in Bartow County, Georgia | The pain syndromes that are caused by transobutrator slings are life-altering.
Our position is that the Obtryx sling is unreasonably dangerous and that there are safer alternative designs and options.”
— Greg Vigna, MD, JD
SANTA BARBARA, CA... |
| 03.05.2023 | Healthcare Veteran, Zach Henderson to lead Global Kinetics as CEO | CHARLOTTE, N.C. and MELBOURNE, Australia, May 3, 2023 /PRNewswire/ -- Global Kinetics, the global leader in digital health solutions for neurological conditions, today announced the appointment of Zach Henderson as its new Chief Executive O... |
| 12.04.2023 | Harvey Washington Wiley campaigned for food and drug safety in the early 20th century. Digital mental health needs its own Wiley moment | Prior to the early 20th century, America had no regulation of medications or food additives. Formaldehyde was used to preserve meat, morphine was included in infant “soothing syrups,” and marketing, not science, drove the promotion of tonic... |
| 10.04.2023 | Don't Let Progressives Assign A Dollar Value To Human Life | WASHINGTON, DC - MARCH 23: Representative Cathy McMorris Rodgers (R-WA), chair of the House Energy ... [+] and Commerce Committee speaks to the media on March 23, 2023 in Washington, DC. (Photo by Tasos Katopodis/Getty Images)Getty Images |
| 06.04.2023 | PVDF has Fewer Complications than Polypropylene in SUI/POP | Dr. Greg Vigna
PVDF has been known to have less inflammatory response and scarring when compared with polypropylene and works in the treatment of SUI with less complications.
The data shows that future PVDF is now for this biomaterial for t... |
| 11.03.2023 | Ethicon and Implanting Physician Hit with TVT-O Sling Lawsuit in Dayton, Ohio | Dr. Greg Vigna
Lawsuit was filed by Ms. TB who was injured by the TVT-O, a polypropylene transobturator sling, used for the surgical management of stress urinary incontinence.
The sling was rushed to market in 2004 and has been injuring wom... |
| 01.03.2023 | 8 Digital Therapies Recommended by NICE | Eight digital therapies for treating mental health have been conditionally recommended by the National Institute for Health and Care and Excellence (NICE).
A consultation on the decision has began for the therapies which address depression ... |
| 18.02.2023 | Girl with rare deadly disease receives revolutionary million-dollar gene-therapy drug – but it is too late for her older sister | Health Girl with rare deadly disease receives revolutionary million-dollar gene-therapy drug – but it is too late for her older sister
Isobel van Hagen
2023-02-18T11:25:36Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The ... |
| 01.02.2023 | MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease | MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease
Wed, Feb 01, 2023 16:00 CET Report this content
PRESS RELEASE - For UK Consumer Health, Medical and Tr... |
| 07.11.2022 | Wake Forest Baptist Health Urogynecologist: “Transobturator slings are done” | Dr. Greg Vigna
Trial data published in New England Journal of Medicine show that mini-slings don't reduce risk of groin pain when compared with full-length mid-urethral slings
The polypropylene mesh health crisis continues as the rate of se... |
| 12.09.2022 | The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients | The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Mon, Sep 12, 2022 15:30 CET Report this content Idefirix® bec... |
| 01.09.2022 | Vigna Law Group: What We Know Now About Single-Incision Mini-Slings | Dr. Greg Vigna
The high rate of dyspareunia (11.7%) with mini-slings deserves further analysis and consideration of whether to implant them in patients who are sexually active
Mini-slings were supposed to substantially reduce risk of chroni... |
| 30.08.2022 | UK-based Neurofenix gets $7 million shot from AlbionVC to boost digital rehab platform | Currently, over 75% of neurologically injured patients, including stroke to traumatic brain injury and spinal cord injury survivors, face long-term disabilities and a lack of functionality because of insufficient neurorehabilitation. In-pat... |
| 30.08.2022 | Albion VC backs neurological rehabilitation platform Neurofenix in €7M round: Know more | London-based Neurofenix, a health tech startup, announced on Monday that it has secured $7M (approximately €7M) in a Series A round of funding led by AlbionVC. HTH, InHealth Ventures, and existing investors also participated in the round.
T... |
| 29.08.2022 | EF alumni Neurofenix raises $7m to help stroke patients | At-home care startup Neurofenix has raised $7m in a Series A, as it looks to improve the rehabilitation process for people who’ve suffered from strokes and other traumatic brain injuries. What does Neurofenix do?
Due to the lack of occupati... |
| 11.08.2022 | NICE Recommendation Expands Patient Eligibility for AbbVie’s Ozurdex[® ](dexamethasone 0.7mg intravitreal implant) in Diabetic Macular Oedema (DMO) | NICE Recommendation Expands Patient Eligibility for AbbVie’s Ozurdex[® ](dexamethasone 0.7mg intravitreal implant) in Diabetic Macular Oedema (DMO)
Thu, Aug 11, 2022 19:31 CET Report this content
PRESS RELEASE - For UK medical and trade med... |
| 05.08.2022 | Vigna Law Group: Investigating Mid-Urethral Sling Complications for Physician Malpractice | Dr. Greg Vigna
The use of mid-urethral slings for the treatment of SUI can be considered dubious, given history of litigation and severe pain syndromes.
Women have been going down with serious pain syndromes that destroy mobility and sexual... |
| 27.07.2022 | Vigna Law Group: Investigating Early Post-Op Pain Following Mid-Urethral Sling | Dr. Greg Vigna
NEJM published that mini-slings that insert into the obturator internus muscle do not reduce the risk of groin pain and are twice as likely to cause dyspareunia
We are now evaluating all cases that involve pain following any ... |
| 19.07.2022 | Heavy-Weight Polypropylene Slings: The End is Near, we hope. | Greg Vigna, MD, JD
NEJM article is just another chapter of the ever-growing history of the failure of heavy-weight polypropylene vaginal mesh devices
The retropubic slings on the market are made of heavy-weight polypropylene that leads to e... |
| 06.07.2022 | Vaginal Mesh Litigation Update: Twice the Risk of Dyspareunia with Mini-Slings | Dr. Greg Vigna
New England Journal of Medicine published evidence that mini-slings carry at least a 2x risk of dyspareunia when compared with full-length mid-urethral slings
The data is very bad for women with these single-incision devices ... |
| 20.06.2022 | Vigna Law Group: New Jersey Vaginal Mesh Cases Moving Forward | Dr. Greg Vigna
The neurological injuries caused by these slings and vaginal mesh will be litigated for decades to come.
Twenty-five percent of women with retropubic slings placed according to the Instructions for Use have the arms in the le... |
| 13.06.2022 | New Research Shows Robotic Surgery Is A Lot Safer | April Fowell, Tech Times 13 June 2022, 11:06 pm
A new study shows that robotic surgery is a lot safer and has a faster recovery period for patients. Robotic surgery helps surgeons to perform various complicated operations with more flexibil... |
| 04.05.2022 | Cabestrillos retropúbicos: un diseño alternativo más seguro del cabestrillo del transobturador | Dr. Greg Vigna
Hay motivos para la negligencia médica simplemente por seleccionar un cabestrillo transobturador de longitud completa o un mini cabestrillo.
Los cabestrillos pesados de polipropileno de longitud completa son irrazonablemente ... |
| 25.04.2022 | Retropubic Slings: Safer Alternative Design to the Transobturator Sling | Dr. Greg Vigna
There is a basis of physician malpractice for merely selecting a full-length transobturator sling or minisling that inserts into the obturator internus muscle.
Our position is that full-length heavy-weight polypropylene retro... |
| 21.04.2022 | icometrix’s MRI measures for people with Multiple Sclerosis receive Medtech Innovation briefing from NICE | icobrain output includes color-coded segmentations in DICOM format, concise reports with normative reference data, and pre-populated reporting templates.
icometrix announced the recent release of a Medtech Innovation Briefing from the inter... |
| 18.04.2022 | Transobturator Slings: Groin Dissection Necessary and Helpful for Intractable Pain | Dr. Greg Vigna
Literature is supporting the efficacy of groin dissection and the removal of the arms of polypropylene slings for women with intractable pelvic pain
The results of this study support that 95% of those who underwent vaginal me... |
| 13.04.2022 | 'Truly different': Roche's former hematology leader shifts a new Versant biotech into gear | Despite a rising threat of antimicrobial resistance, Big Pharma essentially abandoned the field years ago, unable to see past the high risk and poor financial returns. The UK is looking to change that with a new Netflix-style subscription m... |
| 14.02.2022 | Fertility startup raises $20m from Atomico to make IVF accessible to all | London-based fertility startup Gaia today announced it had raised $20m in a Series A funding round led by Atomico. The company is using predictive technology to offer the world’s first-ever insurance product for in vitro fertilisation (IVF)... |
| 14.02.2022 | Combating staggering costs, IVF insurance provider, Gaia, raises $20 million in new round, eyes US expansion | London-based Gaia has raised $20 million in a Series A funding round via Atomico in order to further its mission of enabling more people to become parents. The startup has introduced an IVF insurance product that is underpinned by clinicall... |
| 27.01.2022 | Sedana Medical’s Sedaconda ACD recommended by NICE | Sedana Medical’s Sedaconda ACD recommended by NICE Thu, Jan 27, 2022 08:30 CET
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance re... |
| 27.01.2022 | Sedana Medical's Sedaconda ACD recommended by NICE | Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance recommending Sedaconda ACD as a cost-saving option for delivering inhaled sedatio... |
| 19.01.2022 | Chinese biotech teams with Lilly on cardiometabolic diseases; Senate finance chair goes after BMS | Chinese biotech Abbisko Therapeutics is teaming up with Eli Lilly on a new collaboration.
The pair announced Monday they will partner on cardiometabolic diseases and go after an unnamed target, with Abbisko eligible... |
| 11.01.2022 | NICE recommends AbbVie’s RINVOQ[® ▼ (upadacitinib) ]For Use in Adults with Active Psoriatic Arthritis | NICE recommends AbbVie’s RINVOQ[® ▼ (upadacitinib) ]For Use in Adults with Active Psoriatic Arthritis Tue, Jan 11, 2022 17:50 CET
This decision means that upadacitinib will be available in England and Wales for eligible patients with previo... |
| 16.12.2021 | NICE Recommends VENCLYXTO[®]▼(Venetoclax) Combination in Certain Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia (AML) | NICE Recommends VENCLYXTO[®]▼(Venetoclax) Combination in Certain Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia (AML) Thu, Dec 16, 2021 13:00 CET
Venetoclax in combination with azacitidine will be immediately available to... |
| 22.11.2021 | Gentian Diagnostics : Cystatin C at IFCC EuroMedLab 2021 | Meet us at EuroMedLab - Booth #201
Gentian Diagnostics looks forward to exhibit at IFCC EuroMedLab 2021promoting our turbidimetric cystatin C immunoassay. Visit us at booth #201 to learn more.
Cystatin C - Superior Kidney Marker1
More than ... |
| 04.11.2021 | COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder - Form 6-K | COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy
for post-traumatic stress disorder
London, UK - 3 November 2021
COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to acc... |
| 20.10.2021 | New Quanta survey finds that one-third of UK dialysis patients still not offered the choice of home haemodialysis despite NICE guidelines for COVID | New survey finds that one-third of UK dialysis patients still not offered the choice of home haemodialysis despite NICE guidelines for COVID
ALCESTER, England and BEVERLY, Massachusetts, 20 October 2021: Quanta Dialysis Technologies Ltd (“Q... |
| 07.10.2021 | NICE issues positive Final Appraisal Document for AbbVie’s RINVOQ[®]▼(upadacitinib) in moderate active Rheumatoid Arthritis (RA) | NICE issues positive Final Appraisal Document for AbbVie’s RINVOQ[®]▼(upadacitinib) in moderate active Rheumatoid Arthritis (RA) Thu, Oct 07, 2021 17:16 CET
Positive recommendation means upadacitinib will be available to those with previous... |
| 06.10.2021 | Aetion and NICE Announce Collaboration to Explore Use of Real-World Evidence for Comparative Effectiveness Studies to Inform Clinical Guidance | Collaboration will leverage the Aetion Evidence Platform® to study when and how RWE can support the agency's decision-making
NEW YORK, N.Y. and MANCHESTER, England, Oct. 6, 2021 /PRNewswire/ -- Aetion today announced a collaboration with th... |
| 06.10.2021 | Aetion and NICE Announce Collaboration to Explore Use of Real-World Evidence for Comparative Effectiveness Studies to Inform Clinical Guidance | NEW YORK, N.Y. and MANCHESTER, England, Oct. 6, 2021 /PRNewswire/ -- Aetion today announced a collaboration with the National Institute for Health and Care Excellence (NICE) to explore how real-world evidence (RWE) can be used to study real... |
| 29.09.2021 | Sonova : intensifies holistic approach in Audiological Care business, expanding its services portfolio | Stäfa (Switzerland), 29 September, 2021 - Sonova Holding AG, a leading provider of hearing solutions, is expanding its range of Audiological Care services to support patients with different medical needs often co-existing with hearing loss.... |
| 06.09.2021 | UCB : BIMZELX▼ (bimekizumab) Receives First Positive Health Technology Assessment Worldwide … | · The UK's National Institute for Health and Care Excellence published its final Technology Appraisal Guidance recommending bimekizumab as a treatment option for adults with severe plaque psoriasis
· This first positive health technology as... |
| 19.08.2021 | UK's cost-effectiveness gatekeeper wants to provide faster access to more new drugs | The UK’s arbiter of cost-effectiveness decisions for new drugs, known as the National Institute for Health and Care Excellence or NICE, is plotting a major makeover as the gatekeeper has long been famous for rejecting and... |
| 19.07.2021 | Expanding the public and patient role in medical regulation | Expanding the public and patient role in medical regulation
19-07-2021
A recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI).
Ph... |
| 16.07.2021 | Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer | Bristol Myers Squibb has worked overtime to hunt down an edge for its PD-(L)1 blocker Opdivo over rival Keytruda from Merck, including taking a bold combo strategy with CTLA4 inhibitor Yervoy. But in head and neck cancer,... |
| 03.06.2021 | New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ[®] ▼ (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress | New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ[®] ▼ (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress Thu, Jun 03, 2021 17:51 CET Long-term data from the Phase 3 SELECT-COMPARE... |
| 02.06.2021 | How Can We Tackle Emergency Department Crowding Once And For All? (Part 3 Of 3) | This article is the third in a three-part series which seeks to dissect the challenge of emergency department (ED) crowding; why it occurs, why it’s a problem and what we need to do to overcome it. The creation of this series is driven by t... |
